IMU-935 / IMU-856

About Immunic

Immunic is a clinical-stage biotech focused on developing oral therapies for autoimmune and inflammatory diseases, with a pipeline of eight candidates. Its core strategy is advancing vidofludimus calcium, a DHODH inhibitor, through pivotal trials in multiple sclerosis and ulcerative colitis. The company aims to establish a new standard of care with convenient, orally administered treatments that could improve patient access and outcomes. Success hinges on clinical data readouts, regulatory milestones, and strategic execution in a competitive market.

Therapeutic Areas